Search
Close this search box.

IDIOPATHIC PULMONARY FIBROSIS (ipf)
sndx-6352-0506

ELIGIBILITY & REQUIREMENTS

  • Aged 40 or older
  • Confirmed diagnosis of Idiopathic Pulmonary Fibrosis (IPF)

WHAT'S INVOLVED

  • The trial will run for approximately 44 weeks
  • Eleven clinic visits to the Institute for Respiratory Health at QEII Medical Centre, Nedlands
  • A health check by our doctors and nurses
  • Reimbursement for travel expenses

STUDY OUTLINE

This research study will test Axatilimab solution for intravenous infusion, an investigational drug.

Axatilimab is a humanized IgG4 monoclonal antibody with high affinity against the colony-stimulating factor 1 receptor (CSF-1R). Recent experiments have demonstrated that use of an anti-CSF-1R antibody blocks fibrosis in fibrotic disease models.

In this research study, you will get either intravenous Axatilimab  or placebo, which you will take in addition to your usual IPF medications.

To find out if this trial is suitable for you, please register below, or contact our Clinical Trials Team on 6151 0813 or email clinicaltrials@resphealth.uwa.edu.au

PRINCIPAL INVESTIGATOR

Dr Vidya Navaratnam (Nedlands)

LOCATION

Level 2, 6 Verdun Street Nedlands (within the Harry Perkins Institute)

REGISTER YOUR INTEREST TODAY

* indicates required
Scroll to Top